AstraZeneca (LON:AZN) Now Covered by Analysts at Citigroup

Citigroup started coverage on shares of AstraZeneca (LON:AZN) in a report released on Tuesday, Marketbeat reports. The firm issued a buy rating and a £170 price target on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on the company. Berenberg Bank lifted their price target on AstraZeneca from £142 to £145 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. Jefferies Financial Group reissued a “buy” rating and set a £150 price target on shares of AstraZeneca in a research report on Monday, November 10th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Deutsche Bank Aktiengesellschaft increased their price target on shares of AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a research note on Thursday, January 15th. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of £143.33.

AstraZeneca Trading Down 1.9%

Shares of AstraZeneca stock opened at £136.20 on Tuesday. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. AstraZeneca has a 1 year low of GBX 9,573.51 and a 1 year high of £144.10. The firm has a market cap of £211.15 billion, a PE ratio of 22.62, a PEG ratio of 0.86 and a beta of 0.17. The company has a 50 day simple moving average of £137.69 and a two-hundred day simple moving average of £125.53.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Nazneen Rahman sold 297 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12. Insiders own 0.14% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.